Biohaven Pharmaceutical (BHVN) Upgraded at Zacks Investment Research

Biohaven Pharmaceutical (NYSE:BHVN) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Wednesday.

According to Zacks, “Biohaven Pharmaceutical Holding Company Ltd. is a biopharmaceutical company. It focuses on the identification and development of orphan neurologic indications and other neurological pathways. The company’s pipeline includes BHV-0223, which is a formulation of a glutamate-modulating agent; BHV-4157, which is a new chemical entity that modulates glutamate and BHV-5000, which is an in-licensed investigational agent of the Company targeting N-Methyl-D-Aspartate receptor antagonism which are in clinical trial stage. Biohaven Pharmaceutical Holding Company Ltd. is based in NEW HAVEN, United States. “

A number of other equities analysts have also recently weighed in on the company. Canaccord Genuity started coverage on Biohaven Pharmaceutical in a report on Friday, December 15th. They set a “buy” rating and a $30.00 price objective on the stock. BidaskClub cut Biohaven Pharmaceutical from a “sell” rating to a “strong sell” rating in a research note on Tuesday, November 14th. Piper Jaffray Companies set a $48.00 price target on Biohaven Pharmaceutical and gave the stock a “buy” rating in a research note on Monday, December 11th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $36.00 price target on shares of Biohaven Pharmaceutical in a research note on Wednesday, November 15th. One research analyst has rated the stock with a sell rating, one has given a hold rating and six have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of $36.14.

Shares of Biohaven Pharmaceutical (BHVN) traded down $1.27 during midday trading on Wednesday, hitting $29.90. The company had a trading volume of 225,088 shares, compared to its average volume of 431,413. The stock has a market cap of $1,100.00 and a PE ratio of -5.73. Biohaven Pharmaceutical has a 52 week low of $17.00 and a 52 week high of $39.51.

Biohaven Pharmaceutical (NYSE:BHVN) last announced its quarterly earnings data on Tuesday, November 14th. The company reported ($1.19) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($1.22) by $0.03. equities analysts forecast that Biohaven Pharmaceutical will post -6.4 EPS for the current year.

In other Biohaven Pharmaceutical news, VP Kimberly Gentile sold 5,000 shares of Biohaven Pharmaceutical stock in a transaction that occurred on Thursday, February 1st. The stock was sold at an average price of $32.78, for a total value of $163,900.00. Following the transaction, the vice president now directly owns 5,000 shares of the company’s stock, valued at approximately $163,900. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Gregory Bailey sold 20,600 shares of Biohaven Pharmaceutical stock in a transaction that occurred on Monday, November 27th. The stock was sold at an average price of $25.92, for a total value of $533,952.00. Following the completion of the transaction, the director now directly owns 1,289,699 shares in the company, valued at $33,428,998.08. The disclosure for this sale can be found here. Insiders sold a total of 823,608 shares of company stock worth $23,154,149 over the last ninety days.

Several hedge funds have recently modified their holdings of the company. Goldman Sachs Group Inc. bought a new stake in shares of Biohaven Pharmaceutical in the 4th quarter worth approximately $802,000. Deutsche Bank AG grew its position in shares of Biohaven Pharmaceutical by 28.6% in the 4th quarter. Deutsche Bank AG now owns 23,580 shares of the company’s stock worth $635,000 after buying an additional 5,248 shares during the last quarter. VHCP Management II LLC grew its position in shares of Biohaven Pharmaceutical by 3.3% in the 4th quarter. VHCP Management II LLC now owns 1,718,605 shares of the company’s stock worth $46,368,000 after buying an additional 54,305 shares during the last quarter. Emory University grew its position in shares of Biohaven Pharmaceutical by 28.4% in the 4th quarter. Emory University now owns 74,378 shares of the company’s stock worth $2,007,000 after buying an additional 16,440 shares during the last quarter. Finally, AXA bought a new stake in shares of Biohaven Pharmaceutical in the 4th quarter worth approximately $3,520,000. Hedge funds and other institutional investors own 48.09% of the company’s stock.

TRADEMARK VIOLATION WARNING: This piece of content was originally reported by American Banking News and is the property of of American Banking News. If you are reading this piece of content on another website, it was copied illegally and republished in violation of United States and international copyright & trademark law. The original version of this piece of content can be read at https://www.americanbankingnews.com/2018/02/14/biohaven-pharmaceutical-bhvn-upgraded-at-zacks-investment-research.html.

Biohaven Pharmaceutical Company Profile

Biohaven Pharmaceutical Holding Company Ltd. is a United States-based biopharmaceutical company. The Company is engaged in the identification and development of clinical-stage compounds targeting orphan neurologic indications and other neurological pathways. It has a portfolio of multiple late-stage drug candidates.

Get a free copy of the Zacks research report on Biohaven Pharmaceutical (BHVN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Biohaven Pharmaceutical (NYSE:BHVN)

Receive News & Ratings for Biohaven Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply